Serum anticholinergic activity and cerebral cholinergic dysfunction: An EEG study in frail elderly with and without delirium

Christine Thomas*1,2, Ute Hestermann3, Juergen Kopitz4, Konstanze Plaschke5, Peter Oster3, Martin Driessen2, Christoph Mundt1 and Matthias Weisbrod1

Background: Delirium increases morbidity, mortality and healthcare costs especially in the elderly. Serum anticholinergic activity (SAA) is a suggested biomarker for anticholinergic burden and delirium risk, but the association with cerebral cholinergic function remains unclear. To clarify this relationship, we prospectively assessed the correlation of SAA with quantitative electroencephalography (qEEG) power, delirium occurrence, functional and cognitive measures in a cross-sectional sample of acutely hospitalized elderly (> 80 y) with high dementia and delirium prevalence.

Methods: 61 consecutively admitted patients over 80 years underwent an extensive clinical and neuropsychological evaluation. SAA was determined by using radio receptor assay as developed by Tune, and standard as well as quantitative EEGs were obtained.

Results: 15 patients had dementia with additional delirium (DD) according to expert consensus using DSM-IV criteria, 31 suffered from dementia without delirium (D), 15 were cognitively unimpaired (CU). SAA was clearly detectable in all patients but one (mean 10.9 ± 7.1 pmol/ml), but was not associated with expert-panel approved delirium diagnosis or cognitive functions. Delirium-associated EEG abnormalities included occipital slowing, peak power and alpha decrease, delta and theta power increase and slow wave ratio increase during active delirious states. EEG measures correlated significantly with cognitive performance and delirium severity, but not with SAA levels.

Conclusion: In elderly with acute disease, EEG parameters reliable indicate delirium, but SAA does not seem to reflect cerebral cholinergic function as measured by EEG and is not related to delirium diagnosis.
Background
Additive long lasting anticholinergic side effects of commonly prescribed drugs have recently gained special interest in neuro-geriatric medicine. They are considered one of the main reasons for cognitive decline [1] and delirium in the elderly. Although delirium is a common cause of morbidity and even mortality in the frail elderly and by this has an enormous impact on health economy as well as on individual quality of life, it remains under-diagnosed in elderly patients and especially in concomitant dementia [2]. Multiple causes underlie confusional states, resulting in a common final pathway of probably stress induced neurotransmission imbalances with a predominant cholinergic deficit [2,3]. Frail elderly are especially at risk because of multimorbidity, polypharmacy, accumulated cerebral pathology and physiological age-related changes. The concept of an anticholinergic burden has been established to highlight overall anticholinergic medication effects that could worsen the often impaired cognitive performance in the elderly, and to mark delirium risk.

The anticholinergic burden has been identified using two different approaches.

The first one combines pharmacological knowledge and clinical experience to evaluate the overall central anticholinergic load. [1,4,5] However, mainly peripheral anticholinergic symptoms are screened. The second approach measures the cumulative anticholinergic activity in the peripheral blood utilizing a radio receptor assay developed by Tune in 1980 [6]. This assay detects muscarinic anticholinergic activity in serum samples in comparison to atropine. It has been used to detect global muscarinic anticholinergic properties of various medications [7] and to approve interventions for reducing the anticholinergic burden [8]. Some authors (see [9] for review) found an association of SAA and delirium in various settings, i.e. surgical, ICU- and medical patients [10-12], while some opposing findings exist in oldest old nursing home patients [13]. Cognitive impairment or lower MMSE was associated with higher SAA especially in dementia [9,14,15], depression [16] and community-dwelled elderly [17] but diverging results have also been reported [14,18,19]. It has been presupposed, that this serum assay also reflects the central situation, but this assumption is unproven and has often been questioned [1,20,21]. The CSF-serum-correlation of anticholinergic activity was only reported in two small samples of younger presurgical patients premedicated with central anticholinergics like scopolamine or midazolam [22,23].

The EEG reflects summation potentials of cortical electric activity, modulated by subcortical structures, in an unsurpassed high temporal resolution. The basic EEG alpha rhythm is modulated by cholinergic thalamo-cortical pathways responsible for attention, alertness and vigilance regulation. Inactivity of the arousal system causes a rise of slow activity due to glial influences[24]. Centrally acting anticholinergics such as scopolamine result in occipital rhythm slowing, slow wave increase and decrease of fast activity [25-27], a pattern very similar to the EEG findings in delirium. Because of this distinct pattern, the EEG is still regarded as the gold standard of delirium diagnosis. [26,28] Especially quantitative EEG (qEEG) evaluation has the potential to detect disease- and pharmaco-related powerdensity changes in the different frequency bands [28,29] even in the elderly with and without concomitant dementia.[30,31]

Here we present a cross-sectional and prospective study which aims to investigate the association of anticholinergic burden assessments and EEG parameter in a patient group with high delirium risk: the oldest old suffering acute medical diseases and dementia. We assessed subgroups of these patients including cognitively unimpaired elderly, patients with dementia and patients with additional delirium. We hypothesized that SAA measurement correlates (i) with routine EEG (rEEG) and quantitative EEG (qEEG) parameters and (ii) with functional and cognitive measures. If so SAA would indicate the central cholinergic transmission and would be suitable for the use in delirium screening or prevention as has been recommended[32,33].

Methods
Subjects
All patients older than 80 years and admitted to the University of Heidelberg Geriatric Centre, Bethanien Hospital, on Tuesdays and Fridays for the treatment of an acute disease were consecutively recruited between October 2003 and May 2004. 61 patients and, when appropriate, their legal guardians gave written informed consent. The study was conducted in accordance with the Declaration of Helsinki and was approved by the university’s ethics review board (No.255/2003). All study examinations were conducted on the third day after admission within a 4 hour time frame to limit fluctuation differences. Data evaluation included age, Barthel Index[34] at admission and discharge, length of hospital stay, delirium associated factors (anemia, cachexia, dehydration, acute infections, oxygen saturation, metabolic disturbances, diabetes mellitus, sensory impairment), the number of medications, number of potentially anticholinergic, “delirogenic” medication (corticoids, antibiotics, psychotropic medication, furosemide [7]) and relevant diseases summarized by the Cumulative Illness Rating Scale (CIRS)[35] (see table 1).
Clinical and neuropsychological assessment

A consensus panel, consisting of a geriatric psychiatrist and neurologist and a geriatric medicine specialist, provided diagnosis according DSM-IV criteria. Confusion Assessment Method (CAM)[36,37] was used as a screening tool and diagnosis was based on patient's history, neuropsychological testing, a focused caregiver's interview and the Informed Questionnaire on Cognitive Decline of the Elderly (IQCODE)[38] to ensure diagnostic quality of dementia also. Neuropsychological testing included Mini Mental State Examination (MMSE)[39] and the Short Portable Mental Status Questionnaire (SPMSQ)[40]. Delirium severity was judged by the Delirium Index (DI)[41] The patients were assigned to the following groups according to DSMIV criteria for dementia and delirium:

- Patients with delirium and dementia (DD) (n = 15)
- Demented patients without delirium (D) (n = 31)
- Cognitively unimpaired (CU) (n = 15)

SAA Measurements

Venous blood was collected 1 hour before EEG recording and immediately stored at 4°C for 1 hour until centrifugation (7,000 rpm, 10 min). The supernatant was stored at -80°C until SAA levels were determined. We used the radio receptor assay developed by Tune et al [6] where anticholinergic agents in patients’ serum compete with triitated quinuclidinyl benzilate for mACH-receptors obtained from rat forebrain/striatum homogenate. The displacement of 3H-QNB was used to quantify SAA in comparison to an Atropine standard curve. Detection limit was 0.5 pmol/ml, samples were assessed as one batch. Intra-assay accuracy was always between 93 and 109%, intra-assay precision was always better than 9%, inter-assay accuracy ranged between 95 and 105% (5 spiked serum samples over 3 days at 5, 10, 25 and 50 pmol/ml).

EEG Procedures

EEGs were performed mornings in a shielded, quiet room with artificial light with a computerized 32-channel EEG (Nihon Kohden), 10–20 system including VEOG/HEOG, linked C3C4 as reference, 500 Hz sampling rate, 0.03 Hz and 70 Hz filter settings, impedance below 0.5 kOhm. Patients’ vigilance was optimized by using regular alerts

Table 1: Patient Group and Subgroup Description

| (mean ± SD)         | Cognitively Unimpaired n = 15 | Dementia n = 31 | Delirium with Dementia n = 15 | All patients n = 61 | Statistics |
|---------------------|-------------------------------|-----------------|-------------------------------|---------------------|------------|
| Age                 | 86.9 ± 4.0                    | 86.3 ± 4.8      | 85.3 ± 4.6                    | 86.2 ± 4.5          | F(2,58) = 0.46; p = 0.44 |
| CIRS                | 26.6 ± 4.8                    | 30.5 ± 4.4      | 31.7 ± 5.5                    | 29.9 ± 4.9          | F(2,58) = 0.74; p = 0.48 |
| Dementia type (n)   |                               |                 | 9/5/1 60/33/7%               | 28/14/61/29/8%      |            |
| AD/mixed/VaD        | 19/9/3 61/29/10%              |                 |                               |                     |            |
| Medication amount   |                               |                 |                               |                     |            |
| (Median, range)     | (5.0, 1–12)                  | (5.0, 1–10)     | (6.0, 3–9)                   | (5.0, 1–12)         |            |
| delirogenic         | 1.6 ± 1.6                     | 1.8 ± 1.1       | 2.5 ± 1.4                    | 1.9 ± 1.3           | F(2,58) = 0.23; p = 0.79 |
| medication (Median, range) | (1.0, 0–4)                  | (2.0, 0–4)      | (2.0, 0–5)                   | (2.0, 0–5)          |            |
| Acute Infection     | 1/7%                          | 7/22%           | 3/20%                        | 11/18%              |            |
| days in hospital    | 20.5 ± 17.1                   | 15.1 ± 6.8      | 18.1 ± 7.2                   | 17.2 ± 10.4         |            |
| Barthel admission   | 62.5 ± 31.2                   | 33.7 ± 24.3     | 45.0 ± 18.1                  | 43.9 ± 27.2         |            |
| -ADL discharge      | 75.8 ± 29.0                   | 47.7 ± 31.7     | 61.7 ± 25.1                  | 59.0 ± 31.2         |            |
| IQCODE (norm < 3.3) | 3.1 ± 0.2                     | 4.2 ± 0.6       | 4.2 ± 0.7                    | 4.2 ± 0.7           | F(2,43) = 3.93; p < 0.03 |
| Delirium Index      |                               |                 |                               |                     |            |
| (range 0 – 21)      | 2.5 ± 0.7                     | 6.2 ± 4.0       | 8.7 ± 4.5                    | 6.4 ± 1.1           | H (2, 46) = 7.15; p = 0.028 |
| MMSE (norm > 28 P)  | 28.8 ± 1.8                    | 16.7 ± 7.5      | 14.4 ± 6.0                   | 19.1 ± 8.3          | H (2, 61) = 32.52; p < 0.001 |
| SPMSQ (norm < 2)    | 0.6 ± 0.9                     | 4.7 ± 2.8       | 6.4 ± 2.7                    | 4.1 ± 3.2           | H(2,60) = 27.24; p < 0.001 |
| SAA in pmol/ml      |                               |                 |                               |                     |            |
| (w/o extremes > 2SD)| 9.33 ± 4.44                   |11.03 ± 6.15     |12.25 ± 10.53                 |10.91 ± 7.12         |            |
|                      | (9.33 ± 4.44)                 |(10.27 ± 4.62)   |(9.77 ± 4.47)                 |(9.91 ± 4.48)        |            |

Mean ± SD are shown. AD = Alzheimer Dementia, mixed = AD with vascular pathology, VaD = Vascular Dementia, SAA = Serum Anticholinergic Activity, CIRS = Cumulative Illness Rating Scale, IQCODE = Informant Questionnaire on Cognitive Decline, SPMSQ = Short Portable Mental Status Questionnaire, MMSE = Mini Mental State Examination, Barthel-ADL = Activities of Daily Living. * n = 46 demented patients ANOVA/Kruskal-Wallis statistics and posthoc-testing, with < or > giving the direction of the difference at a significance level of p < 0.01; >> or << specifies direction at a higher significance level of p < 0.001
Spectral analysis data (real and imaginary components) were evaluated on referenced (average reference) EEG using Brain Vision Analyzer software (BrainProducts GmbH, Munich, Germany). FFT data for absolute (aPD) and relative power density (rPD), normalized to 1–20 Hz, were calculated for the parieto-occipital region (averaging O1, O2, O9, O10, P3, P4, Pz, P7, P8) since EEG changes in delirium are most prominent occipitally. AP peak power and peak frequency as well as rPD in 2 Hz-frequency bands (delta 1–3 Hz to alpha2 11–13 Hz) and an aPD-slow wave ratio (A/TD = alpha1+alpha2/theta1+theta2+delta) were obtained and Log10 transformed to minimize skew and kurtosis.

**Statistical analysis**

Group differences were examined using univariate ANOVAs and Duncan's post-hoc-tests. EEG and log-transformed qEEG variables were evaluated by repeated measures ANOVAs (group*frequency bands) followed by one-way ANOVAs for each variable separately or by Kruskal-Wallis-ANOVA. Pearson's correlation coefficients were calculated to evaluate the relation of descriptive variables, EEG parameters and SAA. All statistics were calculated using Statistica 6.0 StatSoft, Inc.

**Results**

The 61 elderly (86.2 ± 4.5 years, 74% female) had been admitted because of acute infection (n = 11/18%), falls (13/21%), cardiac or metabolic disease (9/15%), stroke (5/8%), acute mental disorders (6/10%) and other medical conditions. Five EEG recordings could not be evaluated because of technical artifacts.

**Clinical Data**

Subgroups did not differ with respect to number, age of diagnoses, medication, delirium risk factors or so-called delirogenic medication (table 1). Cognitive impairment was reflected by MMSE and SPMSQ results (p < 0.001) as well as proxies’ IQCODE (p < 0.004). Cognitive impairment was greatest in the delirium group. Delirium Index (DI) demonstrated delirium severity (p < 0.02) No statistical differences were revealed between the delirium plus dementia (DD) and the sole dementia group (D) apart from DI. MMSE and DI correlated in dementia (r = 0.89 and delirium plus dementia (r = 0.78). Cognitive impairment correlated strongly with functional status and functional outcome measured by Barthel-Index (r = 0.55; p < 0.005), but no significant correlations were detected with medication amount, delirogenic medication or overall disease severity (CIRS).

**Serum anticholinergic activity**

SAA samples were obtained in 60 patients. In one demented patient no SAA activity could be detected. As table 1 depicts, no differences in SAA-levels were found between the three groups indicating that neither delirium nor dementia is reflected. There was no significant correlation between SAA levels and age, functional decline (IQCODE), medication amount, delirogenic medication use, delirium severity (DI) and overall disease severity (CIRS). Analysis for the group as a whole yielded a modest negative relation between cognitive performance and anticholinergic burden (fig. 1a). Two patients, however, showed extremely high SAA values (> 2SD) and were thus excluded from further evaluation. An 82 year old woman with admission diagnosis of anticholinergic delirium due to amitryptiline medication had 47 pmol/ml; an 87 year old male with acute pneumonia, fever, severe dementia and 10 different medications, 4 of which had anticholinergic properties, showed 33 pmol/ml. After their exclusion, correlation with cognitive impairment (MMSE) was no longer significant. Functional outcome was significantly correlated with SAA (fig. 1b).

**EEG results**

Delirium cases revealed the highest amount of standard EEG pathology, exhibiting occipital slowing (11/13), theta and/or delta excess (11/13–85% resp. 9/13–69%), insufficient or lost reactivity (13/13) and anteriorization (11/13) in EEG, significantly different from CU (p < 0.01). Table 2 depicts significantly slowed EEG basic rhythm in dementia and even more occipital slowing in DD. QEEG showed significant delta and theta1 increase as well as alpha decrease in DD, resulting in lower slow wave ratio (A/TD) values compared to CU. In comparison to demented patients without delirium, significant delta increase and alpha2 decrease in DD were revealed.

Surprisingly, SAA levels did not correlate with any of the EEG parameters (table 3). Thus, the typical EEG signs of acute encephalopathy depicted in DD (delta increase, alpha2 decrease, A/TD-ratio reduction) did not relate to SAA levels. Also, EEG changes due to dementia as a chronic encephalopathy (peak frequency slowing, theta1 increase) did not correlate with the anticholinergic burden indicator in the group of D or DD (fig. 2).

In contrast, the aforementioned qEEG parameters correlated with cognition (MMSE) (p < 0.005), revealing a negative correlation with slow wave bands, highest with lower theta, and a positive correlation with alpha bands. Similar correlations were found with the DI that under-
**Figure 1**

**Correlation between SAA and cognition and outcome.** Only when extremes (Fig. 1a: top, bottom right) were included into calculation, negative correlation with MMSE reached significance. Excluding extremes (bottom, Fig. 1b) reveals significant correlation with functional outcome.
lined the association of EEG slowing and delirium sever-
ity. Functional outcome (Barthel-Index at discharge) cor-
related highest with both alpha bands (p < 0.05) as is
depicted in table 3.

Discussion
In our prospective, cross-sectional study of SAA, which
has been proposed for delirium screening [7,33], we
detected substantial SAA levels in frail, often demented,
elderly. However, SAA levels revealed to be independent
of delirium and dementia diagnoses and did not correlate
with cognitive impairment. Nor did we find a correlation
with any rEEG or qEEG parameter known to be affected by
the central anticholinergic action of scopolamine [25,27],
and by delirium [26,28]. At least in oldest-old geriatric
inpatients, SAA levels do not seem to reflect the cerebral
situation as measured by clinical means and by EEG.

High SAA levels indicated a significant anticholinergic
burden detectable in the serum of all subgroups of frail
elderly with acute medical conditions, but were not
related to delirium and dementia diagnosis. SAA levels
reported in the literature were measured with comparable
methodology but revealed rather divergent levels [7,9],
presumably due to the different populations studied. Our
SAA levels of frail elderly were in line with those of other
investigations in comparable settings [8,10,14], though
some groups found much smaller SAA in quite similar
patients [9,11,12] especially in patients without delirium.

In our study, SAA levels did not differ in DD patients and
the D or CU subgroups which argues against the hypoth-
esis of a direct relation between delirium and SAA. The
two comparable studies reporting a significant SAA differ-
ence in delirium [10,12] exhibited several methodological

Table 2: Standard EEG and quantitative EEG parameters

|                  | Cognitively Unimpaired | Dementia | Delirium with Dementia | Statistics          |
|------------------|------------------------|----------|------------------------|---------------------|
|                  | n = 13                 | N = 30   | n = 13 (12)            |                     |
| Background activity Hz mean ± SD at rest | 9.05 ± 0.67 | 7.67 ± 1.53 | 7.21 ± 1.12 | F(2,54) = 7.60; p < 0.002; CU >> D >> DD |
| A/TD-ratio       | 1.05 ± 1.10            | 0.60 ± 1.00 | 0.22 ± 1.18 | F(2,46) = 7.24; p < 0.002; CU >> D >> DD |
| rP-Delta μV²/Hz  | 1.21 ± 0.79            | 1.68 ± 0.79 | 2.51 ± 0.92 | F(2,46) = 4.23; p < 0.005; CU < D << DD |
| rP-Theta1 μV²/Hz | 0.62 ± 0.30            | 1.02 ± 0.44 | 1.14 ± 0.65 | F(2,46) = 5.24; p < 0.001; CU >> D >> DD |
| rP-Theta2 μV²/Hz | 1.75 ± 9.6             | 1.77 ± 6.7 | 1.61 ± 0.55 | F(2,46) = 3.12; p < 0.001 |
| rP-Alpha1 μV²/Hz | 2.08 ± 0.94            | 1.24 ± 0.76 | 0.86 ± 0.47 | F(2,46) = 4.23; p < 0.005; CU < D << DD |
| rP-Alpha2 μV²/Hz | 0.59 ± 0.29            | 0.49 ± 0.28 | 0.32 ± 0.15 | F(2,46) = 3.12; p < 0.001 |

Absolute Power(aP) values are given for Peak frequency and alpha/theta+delta ratio, frequency bands are given in relative powerdensity values, mean ± Standard deviation, ANOVA statistics and Duncan posthoc-testing, with < or > giving the direction of the difference at a significance level of p < 0.01; >> or << specifying direction at a higher significance level of p < 0.001.

Table 3: Correlations between QEEG and Cognition, Serum Anticholinergic Activity and Functional Outcome

|                  | MMSE (n = 49) | DI (n = 40) | SAA (n = 47) | BI-ADL admission (n = 45) | BI-ADL Discharge (n = 38) |
|------------------|---------------|-------------|--------------|---------------------------|---------------------------|
|                  | r = 0.53      | r = -0.46   | r = 0.20     | r = 0.01                  | r = 0.23                  |
|                  | p < 0.0001    | p < 0.003   | p = 0.171    | p = 0.96                  | p = 0.174                 |
|                  |               | r = -0.32   | r = 0.16     | r = 0.01                  | r = 0.23                  |
|                  |               | p = 0.027   | r = 0.280    | p = 0.012                 | p = 0.012                 |
|                  |               | r = 0.40    | r = -0.39    | p = 0.04                  | p = 0.004                 |
|                  |               | p = 0.012   | r = -0.39    | p = 0.001                 | p = 0.004                 |

Correlations are given for the whole group without extremes (n = 49). aP/rP = absolute/relative Power, SAA = Serum Anticholinergic Activity, BI-ADL = Barthel Index, DI = Delirium Index; significant results are bold.
Figure 2
Correlation between cognition, functional status and qEEG parameters.
drawbacks. Delirium diagnosis in both studies was based on screening instruments only, without psychiatric evaluation; centrally acting anticholinergic drugs were significantly more common with high SAA and delirium [10, 11]; outlier biases occurred [10] and infection was the strongest delirium predictor. As in our study, SAA did not correlate with definite anticholinergic drugs overall [12]. Also, delirium itself did not correlate with an overall anticholinergic burden but with specific centrally active drugs [42]. Endogenous contributions to SAA, related to fever and infection rather than delirium, and probably mediated through stress mechanisms were recently detected [13, 22, 43]. In animals, stress-induced hyperthermia was found to be modulated by a peripheral cholinergic mechanism [44]. It is therefore hypothesized that stress- and fever related endogenous anticholinergic activity operates in the periphery [22].

In conclusion, SAA must be considered as a conglomerate of anticholinergic properties of endogenous and exogenous origin, which act on peripheral targets and only possibly on the CNS. Our results suggest, that SAA reflects predominantly non-central-acting and medication-independent components in frail oldest old with acute disease.

Typical EEG changes represent the gold standard of delirium diagnosis [26, 28, 30] and our EEG results are in line with these findings in delirium [28, 31] and with dementia studies [26, 45]. REEG and qEEG parameters correlated closely with delirium severity and cognitive impairment underlining their relation to cholinergic activation.

EEG again confirms our expert panel based clinical subgroup classification, but neither REEG nor qEEG parameters correlated with SAA levels. EEG patterns of centrally acting anticholinergics such as scopolamine closely resemble delirium changes in normal [25, 27] and demented subjects [46] while peripheral anticholinergics do not exhibit EEG changes [27, 29]. Thus, the lack of any correlation of SAA with EEG parameters again gives strong evidence that SAA in our sample of frail elderly does not reflect the cerebral cholinergic situation. We confirmed this recently in a younger sample of various ICU patients [47], where SAA levels were found to be lower, but also did not correlate to delirium and EEG measures.

In our frail elderly population no association was observed between the anticholinergic burden and cognitive deficits, not even in dementia. This finding is contrary to previous studies describing an association of SAA with lower MMSE [17, 21, 22], restricted in some to demented patients [9, 14], or to specific memory tests [16]. Others reported no connection in non-demented elderly [14, 19]. Reasons for these discrepancies include: Individual variations due to white matter load [21] and ApoE status [48], which have been shown to influence cognitive performance and cognitive challenge recovery in non-demented elderly. Dose-dependent influences of centrally acting anticholinergics are also probable [14, 22] and may have been overlooked. In Chew’s sample, e.g., most demented subjects had received lorazepam [9], which was recently reconfirmed by fMRI to impair memory [49] and facilitates delirium transition [50]. On the other hand, as MMSE is a rather crude measure of memory functions, slight differences might have been detectable with more sophisticated tests on working memory and delayed recall in our sample, as anticholinergic medication in general has been proven to influence memory function in a subtler way [1, 5].

However, we did find a moderate correlation of SAA with functional outcome, indicating a negative influence of the anticholinergic burden on functional capacity in D and in acutely ill CU, supporting a former study [18]. In DD correlation was lacking, indicating functional deficits caused by additional mechanisms. Functional impairment may be caused by peripheral side effects like accommodation difficulties, brady- or tachycardia and gate disturbance [20]. On the other hand, peripheral cholinergic pathways have also been described to influence memory performance in mice [51], but this awaits confirmation in humans.

Our study has several limitations. A larger sample size might have clarified the correlation with the patients’ daily functions. Additionally, more extensive neuropsychological assessment could evaluate specific but subtle cognitive changes, e.g. memory disturbance. The additional assessment of CSF-AA with SAA and EEG parameters would have strengthened conclusions regarding their association. The correlation of CSF-AA and SAA with individual substances and in different patient samples remains to be assessed. Further studies on the central pharmacodynamics of individual substances and on blood-brain-barrier permeability in the elderly are needed. Finally, our sample did not include delirium patients without a prior cognitive decline. These patients must be studied within a younger patient group with lower dementia prevalence.

**Conclusion**

Our naturalistic cross-sectional study in frail elderly used qEEG and thorough clinical delirium diagnosis (expert consensus) to demonstrate for the first time that SAA levels in frail elderly with acute medical conditions are not delirium-related and therefore cannot be reliably applied for delirium prevention or prediction in this relevant group of patients. SAA seems to reflect primarily the peripheral endogenous and exogenous anticholinergic activity that, as animal research indicates, might also
influence stress-induced thermoregulation and memory performance. Delirium occurrence is, inter alia, dependent on centrally acting anticholinergic mechanisms.

Authors’ contributions
CT and UH conceived the study, participated in its design and coordination and drafted the manuscript. CT evaluated the standard and quantitative EEGs and performed the statistics. JK and KP developed and processed the SAA assays. PO participated in study design, coordination, data interpretation and manuscript drafting. CM and MD participated in study design, data interpretation and critical manuscript revising. MW and MD conceived the study, participated in its design, coordination, data analysis and interpretation and helped drafting the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We are grateful to Kerstin Herwig for providing technical support and data interpretation and manuscript drafting. CM and MD assisted with EEG and psychotherapy – DGGPP) Feb 16, 2007 Mannheim, Germany.

U. Hestermann received a one-year research grant from the women’s support program of the University of Heidelberg. C. Thomas received a habilitation grant from the Medical Faculty of the University of Heidelberg. No conflicting financial interests are to be disclosed for all authors.

References
1. ML Ancelin, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K: Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. Bmj 2006, 332:455-9.
2. Inouye SK: Delirium in older persons. N Engl J Med 2006, 354:1157-65.
3. Trzepacz PT: Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry 2000, 5:132-48.
4. Ness J, Hoth A, Barnett MJ, Shorr RI, Kaboli PJ: Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. Am J Geriatr Pharmacother 2006, 4:42-51.
5. Lechevalier-Michel N, Molinard M, Dartigues JF, Fabrigoule C, Fourrier-Reglat A: Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Br J Clin Pharmacol 2005, 59:143-51.
6. Tune L, Coyle JT: Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch Gen Psychiatry 1980, 37:293-7.
7. Tune LE: Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychopharmacology 2000, 5:149-53.
8. Tollesfson GD, Montague-Clouse J, Lancaster SP: The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population. J Neuropsychiatry Clin Neurosci 1991, 3:214-9.
9. Chew ML, Mulsant BH, Pollock BG: Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am J Geriatr Psychiatry 2005, 13:535-8.
10. Musi C, Ferrari R, Ascani S, Salvioli G: Importance of serum anticholinergic activity in the assessment of elderly patients with delirium. J Geriatr Psychiatry Neurol 1999, 12:82-6.
11. Mach JR Jr, Dysken MW, Kuskowski M, Richelson E, Holden L, Jilk KM: Serum anticholinergic activity in hospitalized older persons with delirium: a preliminary study. J Am Geriatr Soc 1995, 43:491-5.
12. Flacker JM, Cummings V, Mach JR Jr, Bettin K, Kiely DK, Wei J: The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry 1998, 6:31-41.
13. Flacker JM, Lipsitz LA: Serum anticholinergic activity changes with acute illness in elderly medical patients. J Gerontol A Biol Sci Med Sci 1999, 54:M12-M16.
14. Thienhaus OJ, Allen A, Bennett JA, Chopra YM, Zemlan FP: Anticholinergic serum levels and cognitive performance. Eur Arch Psychiatry Clin Neurosci 1990, 240:28-33.
15. Jewart RD, Green J, Lu CJ, Cellar J, Tune LE: Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry 2005, 13:324-8.
16. Nebes RD, Pollock BG, Mulsant BH, Kirshner MA, Halligan E, Zmuda M, Reynolds CF 3rd: Low-level serum anticholinergicity as a source of baseline cognitive heterogeneity in geriatric depressed patients. Psychopharmac Bull 1997, 33:715-20.
17. Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M: Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. J Gerontol B Psychol Sci Soc Sci 2000, 55:56-62.
18. Rovner BW, David A, Lucas-Blautstein MJ, Conklin B, Filip L, Tune L: Self-care capacity and anticholinergic drug levels in nursing home patients. Am J Psychiatry 1988, 145:107-9.
19. Remillard AJ: A pilot project to assess the association of anticholinergic symptoms with anticholinergic serum levels in the elderly. Pharmacotherapy 1994, 14:482-7.
20. Rudd KM, Raihl CL, Bond CA, Abbisscto TJ, Stagehouse AC: Methods for assessing drug-related anticholinergic activity. Pharmacotherapy 2005, 25:1592-601.
21. Nebes RD, Pollock BG, Metzler CC, Saxton JA, Houck PR, Halligan EM, DeKosky ST: Serum anticholinergic activity, white matter hyperintensities, and cognitive performance. Neurology 2005, 65:1487-9.
22. Miller PS, Richardson JS, jyu CA, Lamay JS, Hiscock M, Keegan DL: Association of low serum anticholinergic levels and cognitive impairment in elderly presurgical patients. Am J Psychiatry 1988, 145:342-5.
23. Paschke K, Thomas C, Engelhardt R, Teschedorf P, Hestermann U, Weigand MA, Martin E, Kogart M: Significant correlation between plasma and CSF anticholinergic activity in presurgical patients. Neurosci Lett 2007, 417:16-20.
24. Nunez PL, Wingeier BM, Silberstein RB: Spatial-temporal structures of human alpha rhythms: theory, micorsource corrents, multiscale measurements, and global binding of local networks. Hum Brain Mapp 2001, 13:125-64.
25. Renner UD, Oertel R, Kirch W: Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit 2005, 27:653-65.
26. Brenner RP: Utility of EEG in delirium: past views and current practice. Int Psychogeriatr 1991, 3:211-29.
27. Sloan EP, Fenton GW, Standage KP: Anticholinergic drug effects on quantitative electroencephalogram, visual evoked potential, and verbal memory. Biol Psychiatry 1992, 31:600-6.
28. Jacobson S, Jerrier H: EEG in delirium. Semin Clin Neuropsychopharmacology 2000, 5:86-92.
29. Todorova A, Vanderheith-Guth B, Dimpfel W: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001, 41:636-44.
30. Thomas C, Hestermann U, Walther S, Pfleller U, Hack M, Oster P, Mundt C, Weisbrod M: Prolonged activation EEG differentiates dementia with and without delirium in frail elderly patients. J Neurol Neurosurg Psychiatry 2008, 79:1-9.
31. Jacobson SA, Leuchter AF, Walter DO: Conventional and quantitative EEG in the diagnosis of delirium among the elderly. J Neurol Neurosurg Psychiatry 1993, 56:153-8.
32. Milbrandt EB, Angus DC: Potential mechanisms and markers of critical illness-associated cognitive dysfunction. Curr Opin Crit Care 2005, 11:355-9.
33. Hori K, Funaba Y, Konishi K, Moriyasu M, Hirata K, Oyamada R, Tominaga I, Inada T: Assessment of pharmacological toxicity using serum anticholinergic activity in a patient with dementia. Psychiatry Clin Neurosci 2005, 59:508-10.
34. Mahoney FI, Barthel DW: Functional Evaluation: The Barthel Index. Md State Med J 1965, 14:61-5.

35. Parnelee PA, Thuras PD, Katz IR, Lawton MP: Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995, 43:130-7.

36. Inouye SK, van Dyck CN, Alessi CA, Balkin S, Siegal AP, Horwitz RI: Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990, 113:941-8.

37. Hestermann U, Backenstrass M, Gekle I, Hack M, Oster P, Mundt C, Thomas C: Validation of a German version of the Confusion Assessment Method (CAM) for delirium detection in a sample of acute geriatric patients with high prevalence of dementia. Psychopathology 2008 in press.

38. Jorm AF: A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol Med 1994, 24:145-53.

39. Inouye SK, van Dyck CN, Katz IR, Krupat O, Dittus RS, Deschamps G: "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1990, 12:189-98.

40. Pfeiffer E: A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975, 23:433-41.

41. McCusker J, Cole MG, Dendukuri N, Belzile E: The delirium index, a measure of the severity of delirium: new findings on reliability, validity, and responsiveness. J Am Geriatr Soc 2004, 52:1744-9.

42. Gaudreau JD, Gagnon P, Harel F, Roy MA, Tremblay A: Psychoactive medications and risk of delirium in hospitalized cancer patients. J Clin Oncol 2005, 23:6712-8.

43. Flacker JM, Wei JY: Endogenous anticholinergic substances may exist during acute illness in elderly medical patients. J Gerontol A Biol Sci Med Sci 2001, 56:M33-5.

44. Johnson Rowsey P, Yang YL, Gordon CJ: Peripheral cholinergic pathway modulates hyperthermia induced by stress in rats exposed to open-field stress. J Appl Physiol 2002, 92:789-94.

45. Hiele K van der, Vein AA, Reijntjes RH, Westendorp RG, Bollen EL, van Buchem MA, van Dijk JG, Middelkoop HA: EEG correlates in the spectrum of cognitive decline. Clin Neurophysiol 2007.

46. Ebert U, Kirch W: Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest 1998, 28:944-9.

47. Plaschke K, Hill H, Engelhardt R, Thomas C, von Hasen R, Scholz M, Kopitz J, Bardenheuer HJ, Weisbrud M, Weigand MA: EEG changes and serum anticholinergic activity measured in patients with delirium in the intensive care unit. Anaesthesia 2007, 62:1217-23.

48. Pomara N, Willoughby L, Wesnes K, Greenblatt DJ, Sidis JJ: Apolipoprotein E epsilon4 allele and lorazepam effects on memory in high-functioning older adults. Arch Gen Psychiatry 2005, 62:209-16.

49. Sperling R, Greve D, Dale A, Killiany R, Holmes J, Rosas HD, Cocchiarella A, Firth P, Rosen B, Lake S, et al: Functional MRI detection of pharmacologically induced memory impairment. Proc Natl Acad Sci USA 2002, 99:453-60.

50. Pandharipande P, Shintani A, Peterson J, Pun BT, Wilkinson GR, Dittus RS, Bernard GR, Ely EW: Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006, 104:21-6.

51. Lawson CJ, Homewood J, Taylor AJ: The Effects of L-glucose on memory in mice are modulated by peripherally acting cholinergic drugs. Neurobiol Learn Mem 2002, 77:17-28.